The organ-on-chip market is anticipated to grow at a CAGR of 21.3% till 2035, claims Roots Analysis
October 18, 2022 08:00 ET
|
Roots Analysis
London, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Organ on a Chip Market, 2022-2035: Focus on Products and Technologies” report to its list of offerings. With...
The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis
July 27, 2022 10:00 ET
|
Roots Analysis
London, July 27, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Gene Therapy Market” report to its list of offerings. Post the emergence of blockbuster gene therapies, such...
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
June 03, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
May 12, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and...
Decibel Therapeutics to Participate in Upcoming Investor Conferences
March 22, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
December 06, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
November 22, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
Collaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development...
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
November 08, 2021 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
September 30, 2021 17:42 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
The Fc protein and glyco-engineered antibodies market is projected to grow at a CAGR of over 30% during 2021-2030, claims Roots Analysis
September 14, 2021 08:15 ET
|
Roots Analysis
London, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings. Over time, a...